Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ototoxicity associated with vinblastine.

P E Moss1, S Hickman, B R Harrison

  • 1St. Louis College of Pharmacy, MO, USA.

The Annals of Pharmacotherapy
|May 20, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computed tomography of traumatic abdominal wall hernias: recognition, associated injuries, and impact on management in blunt trauma.

Clinical radiology·2026
Same author

Upper limb computed tomography (CT) angiography in the emergency department.

Clinical radiology·2024
Same author

Report from the Annual Conference of the British Society of Echocardiography, October 2018, ACC Liverpool, Liverpool.

Echo research and practice·2020
Same author

<i>Streptococcus constellatus</i> Causing Empyema and Sepsis, Necessitating Early Surgical Decortication.

Case reports in infectious diseases·2020
Same author

Dermoscopy for melanoma detection and triage in primary care: a systematic review.

BMJ open·2019
Same author

Artificial intelligence in breast imaging.

Clinical radiology·2019

This case study highlights potential ototoxicity from vinblastine chemotherapy. Tinnitus and hearing loss were observed in a patient receiving ABVD treatment, suggesting vinblastine as a possible cause.

Area of Science:

  • Oncology
  • Ototoxicology
  • Pharmacology

Background:

  • Chemotherapy regimens like ABVD are standard for Hodgkin's disease.
  • Vinca alkaloids are commonly used in cancer treatment.
  • Ototoxicity is a known side effect of some chemotherapy agents.

Observation:

  • A patient undergoing ABVD chemotherapy for Hodgkin's disease experienced tinnitus and mild sensorineural hearing loss.
  • Symptoms of tinnitus began approximately six hours after each treatment cycle and lasted several days.
  • Audiograms confirmed high-frequency hearing loss, though speech recognition remained intact.

Findings:

  • The patient's ototoxicity symptoms were temporally associated with vinblastine administration within the ABVD regimen.
  • No other medications were identified as the cause of the observed ototoxicity.

Related Experiment Videos

  • Literature review revealed no prior reports of ototoxicity specifically linked to the ABVD regimen.

    • Implications:

    • This case suggests a potential ototoxic effect of vinblastine, a vinca alkaloid.
    • Further investigation into vinblastine-induced ototoxicity is warranted.
    • Clinicians should monitor for auditory side effects in patients receiving vinblastine-containing chemotherapy.